Abeona Therapeutics Inc.
NASDAQ:ABEOBiotechnology
+$0.06 today
- Market cap
- $156.01M
- Beta
- 1.35
- P/E (TTM)
- 4.9
- EPS (TTM)
- $1.17
Volume 1.71M
Average 1.12M
ABEO Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Abeona Therapeutics Inc.NASDAQ: ABEO
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin at 59.1%
Gross margin was 59.1% in Q1 FY2026. On a trailing-twelve-month basis it was 51.9%. Over 3 fiscal years it widened by 5.5 pp.
Context
- Gross margin widened in 1 of the last 2 fiscal years.
- FY2025 was the highest level in the 3 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 73.7%
- Year-over-year change
- —
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 73.7% | — |
| FY2024 | 2024-12-31 | — | — |
| FY2023 | 2023-12-31 | 54.1% | -14.0pp |
| FY2022 | 2022-12-31 | 68.2% | -31.8pp |
| FY2021 | 2021-12-31 | 100.0% | — |
Gross Margin vs competitors
How ABEO compares with its peers on the latest reported figures
- ABEO's LTM Mar 2026 gross margin of 51.9% is the 5th highest of the 8 companies compared; the peer median is 74.5%.
- Over three fiscal years its change of +5.5 pp compares with a peer median of -4.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 144.9% | — | — | |
| LTM Mar 2026 | 91.2% | -8.8 pp | -4.5 pp | |
| LTM Mar 2026 | 77.2% | +110.0 pp | — | |
| LTM Mar 2026 | 74.5% | +2.1 pp | -1.3 pp | |
| LTM Mar 2026 | 51.9% | — | +5.5 pp | |
| LTM Mar 2026 | 22.3% | -77.7 pp | -10.8 pp | |
| LTM Mar 2026 | -86.7% | +2.3 pp | +136.3 pp | |
| LTM Mar 2026 | -748.5% | -729.4 pp | -309.0 pp | |
SGMTSagimet Biosciences Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding ABEO) | 74.5% | -3.4 pp | -4.5 pp | |
Competitors are the stored peer set for ABEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3M | 1.41M | 3.5M | 0 | 5.82M |
| Cost of Revenue | 0 | 450K | 1.61M | 2.91M | 1.53M |
| Gross Profit | 3M | 964K | 1.9M | (2.91M) | 4.29M |
| Gross Margin | 100.0% | 68.2% | 54.1% | — | 73.7% |
| Research & Development | 38.73M | 28.97M | 31.09M | 34.36M | 26.81M |
| Selling, General & Admin | 21.64M | 17.26M | 19M | 29.85M | 65.03M |
| Operating Expenses | 92.84M | 51.88M | 49.03M | 61.3M | 93.74M |
| Depreciation & Amortization | 4.46M | 4.58M | 3.2M | 2.91M | 3.56M |
| EBITDA | (76.82M) | (34.38M) | (50.57M) | (56.62M) | 78.59M |
| EBITDA Margin | -2560.5% | -2431.6% | -1444.9% | — | 1350.3% |
| Operating Income | (89.84M) | (50.92M) | (47.14M) | (64.21M) | (89.45M) |
| Operating Margin | -2994.5% | -3600.8% | -1346.7% | — | -1536.9% |
| Interest Income | 40K | 431K | 2.12M | 4.25M | 5.56M |
| Interest Expense | 3.66M | 736K | 418K | 4.21M | 3.74M |
| Other Income / Expenses | 4.9M | 11.22M | (7.05M) | 477K | 160.73M |
| Income Before Tax | (84.94M) | (39.7M) | (54.19M) | (63.73M) | 71.28M |
| Pre-Tax Margin | -2831.2% | -2807.4% | -1548.2% | — | 1224.8% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 100K |
| Net Income | (84.94M) | (39.7M) | (54.19M) | (63.73M) | 71.18M |
| Net Margin | -2831.2% | -2807.4% | -1548.2% | — | 1223.1% |
| EPS (Basic) | (21.50) | (5.53) | (2.53) | (1.55) | 1.34 |
| EPS (Diluted) | (21.50) | (5.53) | (2.53) | (1.55) | 1.01 |
| Weighted Avg Shares | 3.94M | 7.86M | 21.38M | 41.05M | 52.95M |
| Weighted Avg Shares (Diluted) | 3.94M | 7.86M | 21.38M | 41.05M | 66.14M |
Abeona Therapeutics Inc.
NASDAQ:ABEO
Intrinsic Alpha fair value
Locked
Current Price
$2.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.